| Poster Featuring Misonix BoneScalpel(TM) Wins Best in Show Award at 62nd Neurological Society of India Annual Conference | FARMINGDALE, N.Y., Jan. 30, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced that a scientific poster titled "BoneScalpel -- A cutting edge technology" won the Best Poster Award at the 62(nd) Annual Conference of the Neurological Society of India (NSICON) in Mumbai held December 11-15, 2013.
The Neurological Society of India is the apex body representing neuroscientists in India. Its annual meeting was attended by 800 neurosurgeons from South Asia. Since its inception, the Society has been involved in organizing seminars and conferences to initiate interaction between practicing neurologists and keeping the neuroscientist community up-to-date with the latest developments in the field. The Indian society expresses its mission with the following statement: "We are 1.5% of the world's neuroscientists working on the neurological afflictions of every sixth human on the planet."
The Grant Medical College in Mumbai is one of the premier medical institutions in India and consistently being ranked as one of the top 10 medical colleges in the country. Their advanced team of neurosurgeons is led by Dr. V. Velho together with his predecessor Dr. A Palande and lead author of the award-winning poster Dr. H. Kharosekar concludes that BoneScalpel is setting a new standard for surgical bone removal technologies at their institution with important benefits over traditional methods.
The college's neurologists reviewed 50 neurosurgical procedures ranged from opening of the cranium (craniotomy) over nerve decompression in the spinal canal to harvesting bone segments for re-implantation. The absence of incidental tears to spinal and cranial dura is below published findings for comparable technologies and showcases BoneScalpel's ability to minimize trauma to adjacent nerves and vessels. In addition, use of BoneScalpel resulted in better cosmetic results after surgically opening the cranium. Dr. Velho and his colleagues are adamant about the BoneScalpel's innovativeness. They state "BoneScalpel is a safe and effective ultrasonic device that is useful in osteotomies in various cranial and spinal procedures. The device allows precision bone cutting with minimal bone and blood loss and obviates the risk associated with the use of high speed burr and also saves time."
Michael A. McManus, Jr., President and Chief Executive Officer of Misonix comments, "We are seeing increasing evidence from around the world that BoneScalpel is superior to traditional methods of cutting bone in surgery. More and more groups of surgeons are experiencing important reductions in blood loss, loss of bone and operative time. We have every reason to believe that ultrasonic technology, namely our Misonix BoneScalpel, will set new surgical standards for bone removal in orthopedic and neurological procedures."
About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Company Contact: Investor Contacts: Richard Zaremba Robert Blum, Joe Dorame, Joe Diaz Misonix, Inc. Lytham Partners, LLC 631-694-9555 602-889-9700 invest@misonix.com mson@lythampartners.com www.misonix.com www.lythampartners.com
SOURCE Misonix, Inc. |
